The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The efficacy of trastuzumab-deruxtecan for the treatment of patients with advanced HER2-low breast cancer

Published:2023-09-12 Issue: Volume: Page:1-8
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Schlam Ilana¹,Tolaney Sara M.²,Tarantino Paolo²³

Affiliation:

1. Department of Hematology and Oncology, Tufts Medical Center, Boston, MA, USA

2. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

3. Division of New Drugs and Early Drug Development, European Institute of Oncology IRCCS, University of Milan, Milan, Italy

Funder

funding

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2023.2171993

Reference71 articles.

1. Global patterns of breast cancer incidence and mortality: A population‐based cancer registry data analysis from 2000 to 2020

2. Breast cancer statistics, 2019

3. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

4. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP